Thanks for your insights, but Vical is designed to be a therapeutic vaccine, not a cure as with Frazer's. It doesn't appear to be much more effective than valocyclovir (Valtrex) in initiating adequate T cell response.
Yes, there is plenty of competition. But Coridon's codon optimisation tech puts us ahead as it can be implemented to target a range of other viruses.
updated ballieu report - target range 25-55c, page-53
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.40 |
Change
0.310(2.05%) |
Mkt cap ! $325.5M | |||
| Open | High | Low | Value | Volume |
| $15.57 | $15.84 | $15.15 | $452.1K | 29.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.40 | 2886 | 1 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |